Skip to main content

Table 3 Adverse events in treated obese girls (rhGH+) and untreated obese girls (rhGH -)

From: Effects of recombinant human growth hormone (rhGH) administration on body composition and cardiovascular risk factors in obese adolescent girls

Event type

Total number of adverse events

Adverse events

RhGH + (N)

RhGH - (N)

Serious adverse events

-

-

-

Non-serious adverse events

   

Hyperglycemia related events

   

IGT at 3 or 6-month (OGTT)

6

2

4

Polyuria/Polydipsia

4

3

1

HbA1c > 6.4%

1

1

-

Symptoms that may relate to raised ICP

   

Headache

7

4

3

Nausea with vomiting

1

1

-

Nausea without vomiting

3

3

-

Dizziness without headache

1

-

1

Blurry vision

1

1

-

Arthralgias/Fluid retention related events

   

Arthralgia

2

2

-

Back pain

5

4

1

Myalgia

1

1

-

Edema

-

-

-

Menstrual cycle related events

   

Change in menstrual Flow

5

3

2

Injection related events

   

Bruising/Irritation at injection site

4

2

2

Bruising/Irritation at blood sampling site

1

1

-

Others

   

Hypertension

1

-

1

Lightheadedness

-

-

-

ED visit for wheezing with URI

1

-

1

Abdominal pain

2

2

-

Upper respiratory Infection

1

1

-

Nasal congestion (with URI)

1

1

-

Fatigue

2

-

2

Eczema

1

-

1

  1. RhGH+: Group that received rhGH; RhGH-: Group that received placebo/no treatment.
  2. Abbreviations: ED emergency department, ICP intracranial pressure, IGT impaired glucose tolerance, OGTT oral glucose tolerance test, URI upper respiratory infection.
  3. There were no significant differences across the two groups for the various adverse events.